An 88% reduction in hospitalization or death is a number that changes the calculus of the pandemic for high-risk patients. That is the headline figure attached to Paxlovid, the oral antiviral treatment developed by Pfizer, and it represents a concrete, measurable shift in what doctors can offer people who get sick.
The drug is not a single compound. It is a co-packaged combination of two antivirals: nirmatrelvir and ritonavir. Nirmatrelvir does the heavy lifting by inhibiting the SARS-CoV-2 main protease, essentially gumming up the virus’s ability to replicate. Ritonavir plays a supporting role. It acts as a strong CYP3A inhibitor, meaning it slows down how fast the body breaks down nirmatrelvir, keeping the active drug in the system longer and boosting its effect. The result is a treatment that can be taken orally—pills, not an IV—which makes it a practical option for people infected at home.
As of May 15, 2023, regulatory agencies in the United States, the United Kingdom, the European Union, and Canada have given the drug approval for treating mild-to-moderate COVID-19. The approval is not universal, but it covers a significant portion of the developed world. The real stakes are visible in the timing requirement. The 88% risk reduction only holds if the medication is taken within five days of symptom onset. Miss that window, and the benefit drops sharply. For a patient waking up with a cough and a positive test, those five days are the difference between a course of pills and a hospital bed.
The clinical data also shows a secondary benefit. People who take Paxlovid test negative for the virus about two and a half days earlier than those who do not. That is not just a matter of personal inconvenience. Shorter viral shedding means less time to infect others, which matters for households, workplaces, and nursing homes where a single case can spiral.
But the drug is not free of trade-offs. Common side effects include dysgeusia—a persistent, often metallic change in the sense of taste—along with diarrhea, hypertension, and muscle pain. These are not trivial. A patient who stops the five-day course early because of side effects risks losing the antiviral protection. The medication also interacts with a long list of common drugs, precisely because of the ritonavir component that boosts nirmatrelvir. Doctors have to weigh those interactions before writing a prescription.
For high-risk individuals—the elderly, the immunocompromised, people with underlying conditions—the stakes are life and death. An 88% reduction means that out of every 100 people who would have ended up hospitalized or dead, roughly 88 will not. That is direct, individual-level protection. It does not replace vaccines, which work on the front end to prevent infection. It is a backup, a second line of defense for when the first line fails.
The convenience of an oral pill matters. It takes pressure off hospitals already strained by seasonal surges. It allows a patient to be treated at home, reducing exposure for healthcare workers and preserving bed capacity for other emergencies. In a pandemic that has killed millions, a pill that cuts severe outcomes by nearly nine-tenths is a genuine advance. The question now is access—whether patients can get it within that five-day window, and whether the side effects and drug interactions will limit its real-world use.
